MedPage Today on MSNOpinion
Spotting Trends in Patients' Tests
Statistics, and the standard deviation of our tests, mean that if you order a complete metabolic profile, a lipid panel, a ...
18hon MSN
Nearly 90% of adults are at risk for this condition, but most have never heard of it, survey finds
About 9 in 10 adults in the United States have not heard of cardiovascular-kidney-metabolic syndrome despite nearly 90% of ...
The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by Genentech, as a treatment for adults with lupus nephritis (LN), also known as lupus-related kidney disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback